Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 258-266 , October 2010

The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel Strategies for Prostate Cancer Radiotherapy

References 

  1. Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: Anti-apoptotic p53. Cell Death Differ. 2008;15:959–976
  2. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell. 2006;21:307–315
  3. Sherr CJ. Divorcing ARF and p53: An unsettled case. Nat Rev Cancer. 2006;6:663–673
  4. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: Research tools and potential therapeutics. Cell Cycle. 2004;3:419–421
  5. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103–112
  6. Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst). 2004;3:1071–1079
  7. Grignon DJ, Caplan R, Sarkar FH. p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. and others J Natl Cancer Inst. 1997;89:158–165
  8. Khor LY, Desilvio M, Al-Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group protocol 8610. Cancer. 2005;104:962–967
  9. Chakravarti A, Heydon K, Wu CL, et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol. 2003;21:3328–3334
  10. Chakravarti A, DeSilvio M, Zhang M, et al. Prognostic value of p16 in locally advanced prostate cancer: A study based on Radiation Therapy Oncology Group protocol 9202. J Clin Oncol. 2007;25:3082–3089
  11. Li R, Heydon K, Hammond ME, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in Radiation Therapy Oncology Group protocol 86-10. Clin Cancer Res. 2004;10:4118–4124
  12. Pollack A, DeSilvio M, Khor LY, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02. J Clin Oncol. 2004;22:2133–2140
  13. Pochampally R, Fodera B, Chen L, et al. A 60 Kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene. 1998;17:2629–2636
  14. Meek DW. Tumour suppression by p53: A role for the DNA damage response?. Nat Rev Cancer. 2009;9:714–723
  15. Zhang Z, Wang H, Li M, et al. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene. 2005;24:7238–7247
  16. Seo YR, Fishel ML, Amundson S, et al. Implication of p53 in base excision DNA repair: In vivo evidence. Oncogene. 2002;21:731–737
  17. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell. 2004;13:627–638
  18. Chen J, Sadowski I. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci U S A. 2005;102:4813–4818
  19. Warnick CT, Dabbas B, Ford CD, et al. Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells. J Biol Chem. 2001;276:27363–27370
  20. Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci U S A. 2002;99:12985–12990
  21. Ofir-Rosenfeld Y, Boggs K, Michael D, et al. Mdm2 Regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol Cell. 2008;32:180–189
  22. Polager S, Ofir M, Ginsberg D. E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene. 2008;27:4860–4864
  23. Marti A, Wirbelauer C, Scheffner M, et al. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol. 1999;1:14–19
  24. Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell. 2008;13:11–22
  25. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001;15:1833–1844
  26. Maser RS, Mirzoeva OK, Wells J, et al. Mre11 Complex and DNA replication: Linkage to E2F and sites of DNA synthesis. Mol Cell Biol. 2001;21:6006–6016
  27. Liu K, Lin FT, Ruppert JM, et al. Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol Cell Biol. 2003;23:3287–3304
  28. Speidel D. Transcription-independent p53 apoptosis: An alternative route to death. Trends Cell Biol. 2009;20:14–24Nos
  29. Polager S, Ginsberg D. p53 and E2F: Partners in life and death. Nat Rev Cancer. 2009;9:738–748
  30. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010–1014
  31. Leu JI, Dumont P, Hafey M, et al. Mitochondrial p53 activates bak and causes disruption of a bak-Mcl1 complex. Nat Cell Biol. 2004;6:443–450
  32. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11:577–590
  33. Bennett M, Macdonald K, Chan SW, et al. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science. 1998;282:290–293
  34. Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53. Nature. 1998;395:124–125
  35. Mason SL, Loughran O, La Thangue NB. p14(ARF) regulates E2F activity. Oncogene. 2002;21:4220–4230
  36. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, et al Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000;407:645–648
  37. Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A. 2003;100:10848–10853
  38. Zindy F, Eischen CM, Randle DH, et al. Myc Signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12:2424–2433
  39. Tolbert D, Lu X, Yin C, et al. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol Cell Biol. 2002;22:370–377
  40. Rogoff HA, Pickering MT, Debatis ME, et al. E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol Cell Biol. 2002;22:5308–5318
  41. Russell JL, Powers JT, Rounbehler RJ, et al. ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol Cell Biol. 2002;22:1360–1368
  42. Tsai KY, MacPherson D, Rubinson DA, et al. ARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol. 2002;12:159–163
  43. Nguyen KH, Hachem P, Khor LY, et al. Adenoviral-E2F-1 radiosensitizes p53(wild-type) and p53(null) human prostate cancer cells. Int J Radiat Oncol Biol Phys. 2005;63:238–246
  44. Udayakumar TS, Hachem P, Ahmed MM, et al. MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation. Mol Cancer Res. 2008;6:1742–1754
  45. Johnson DG, Cress WD, Jakoi L, et al. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci U S A. 1994;91:12823–12827
  46. Hsieh JK, Yap D, O'Connor DJ, et al. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol. 2002;22:78–93
  47. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 1995;375:694–698
  48. Martin K, Trouche D, Hagemeier C, et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature. 1995;375:691–694
  49. Hsieh JK, Chan FS, O'Connor DJ, et al. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell. 1999;3:181–193
  50. Sdek P, Ying H, Chang DL, et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell. 2005;20:699–708
  51. Sdek P, Ying H, Zheng H, et al. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem. 2004;279:53317–53322
  52. Kowalik TF, DeGregori J, Leone G, et al. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ. 1998;9:113–118
  53. Yang HL, Dong YB, Elliott MJ, et al. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells. Clin Cancer Res. 1999;5:2242–2250
  54. Zhang Z, Li M, Wang H, et al. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003;100:11636–11641
  55. Wunderlich M, Berberich SJ. Mdm2 Inhibition of p53 induces E2F1 transactivation via p21. Oncogene. 2002;21:4414–4421
  56. Bottger A, Bottger V, Sparks A, et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997;7:860–869
  57. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 1997;15:1179–1189
  58. Lehman JA, Eitel JA, Batuello CN, et al. Therapeutic considerations for Mdm2: Not just a one trick pony. Expert Opin Drugs Discov. 2008;3:1309–1321
  59. Bouska A, Lushnikova T, Plaza S, et al. Mdm2 Promotes genetic instability and transformation independent of p53. Mol Cell Biol. 2008;28:4862–4874
  60. Mu Z, Hachem P, Agrawal S, et al. MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int J Radiat Oncol Biol Phys. 2004;58:336–343
  61. Roach M, Waldman F, Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer. 2009;115:3112–3120(suppl)
  62. Khor LY, Desilvio M, Li R, et al. Bcl-2 and Bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys. 2006;66:25–30
  63. Chakravarti A, Heydon K, Wu CL, et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol. 2003;21:3328–3334
  64. Khor LY, Bae K, Al-Saleem T, et al. Protein kinase A RI-alpha predicts for prostate cancer outcome: Analysis of Radiation Therapy Oncology Group trial 86–10. Int J Radiat Oncol Biol Phys. 2008;71:1309–1315
  65. Zhang M, Ho A, Hammond EH, et al. Prognostic value of survivin in locally advanced prostate cancer: Study based on RTOG 8610. Int J Radiat Oncol Biol Phys. 2009;73:1033–1042
  66. Khor LY, Bae K, Paulus R, et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer RTOG, p 92, p 92. J Clin Oncol. 2009;27:3177–3184
  67. Che M, DeSilvio M, Pollack A, et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: A study based on RTOG 9202. Int J Radiat Oncol Biol Phys. 2007;69:1117–1123
  68. Khor LY, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92-02. Clin Cancer Res. 2007;13:3585–3590
  69. Khor LY, Bae K, Pollack A, et al. Cox-2 expression predicts prostate-cancer outcome: Analysis of data from the RTOG 92-02 trial. Lancet Oncol. 2007;8:912–920
  70. Pollack A, Bae K, Khor LY, et al. The importance of protein kinase A in prostate cancer: Relationship to patient outcome in Radiation Therapy Oncology Group Trial 92-02. Clin Cancer Res. 2009;15:5478–5484
  71. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–591
  72. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497–2504
  73. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972–3978
  74. Pollack A, Bae K, Khor LY, et al. A model for distant metastasis incorporating tissue biomarkers from prostate cancer patients in Radiation Therapy Oncology Group (RTOG) 92-02. Boston. 2008;S58;p Supplement
  75. Vergis R, Corbishley CM, Thomas K, et al. Expression of Bcl-2, p 53 and MDM2, in Localized Prostate Cancer with Respect to the Outcome of Radical Radiotherapy Dose Escalation. Int J Radiat Oncol Biol Phys. 2010;in press

PII: S1053-4296(10)00041-X

doi: 10.1016/j.semradonc.2010.05.007

Seminars in Radiation Oncology
Volume 20, Issue 4 , Pages 258-266 , October 2010

Article Tools

* Image Usage & Resolution